Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric Acidity

Background: DLBS2411, A bioactive fraction derived from the bark of Cinnamomum burmanii has been developed to address acid-related gastrointestinal disorders. This study evaluated the pharmacodynamic effect of DLBS2411 on the 24-hour intragastric acidity in healthy adults.  Methods: In a 3-arm, pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Raymond Rubianto Tjandrawinata, Murdani Abdullah, Marcellus Simadibrata, Liana W Susanto, Kaka Renaldi
Format: Article
Language:English
Published: Interna Publishing 2025-04-01
Series:The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Subjects:
Online Access:https://ina-jghe.com/index.php/jghe/article/view/1059
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849730546088804352
author Raymond Rubianto Tjandrawinata
Murdani Abdullah
Marcellus Simadibrata
Liana W Susanto
Kaka Renaldi
author_facet Raymond Rubianto Tjandrawinata
Murdani Abdullah
Marcellus Simadibrata
Liana W Susanto
Kaka Renaldi
author_sort Raymond Rubianto Tjandrawinata
collection DOAJ
description Background: DLBS2411, A bioactive fraction derived from the bark of Cinnamomum burmanii has been developed to address acid-related gastrointestinal disorders. This study evaluated the pharmacodynamic effect of DLBS2411 on the 24-hour intragastric acidity in healthy adults.  Methods: In a 3-arm, parallel, double-blind, randomized, placebo-controlled clinical trial, healthy subjects received a single dose of DLBS2411 (250 mg or 500 mg) or placebo. Gastric pH was monitored, analyzed and profiled over 24 hours. Results: Of a total of 54 enrolled male subjects, 47 subjects (87.04%) were eligible for the analysis. The mean 24-hour intragastric pH for DLBS2411 250 mg and 500 mg was 2.29 ± 0.42 and 2.13 ± 0.50, respectively, both higher than placebo (1.93 ± 0.70). Differences were more pronounced during the first 12 hours (daytime). DLBS2411 250 mg and 500 mg reached a gastric pH 4 significantly faster (129.9 ± 128.2 and 92.9 ± 106.8 minutes) compared to placebo (196.9 ± 99.7 minutes). No serious adverse events occurred. All adverse events were mild and had been resolved by the end of study, confirming the safety and tolerability of DLBS2411 at the dose of 250 and 500 mg. Conclusion: DLBS2411 effectively suppressed the intragastric acidity and demonstrated a good safety profile in healthy adults. These findings warrant further studies of DLBS2411 in patients with gastric acid-related disorders. Keywords: Alternative medicine, DLBS2411 cinnamomum burmanii, healthy volunteers, intragastric-acidity, proton pump inhibitors
format Article
id doaj-art-d3a5becea492436fb01d79e9a20159b3
institution DOAJ
issn 1411-4801
2302-8181
language English
publishDate 2025-04-01
publisher Interna Publishing
record_format Article
series The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
spelling doaj-art-d3a5becea492436fb01d79e9a20159b32025-08-20T03:08:51ZengInterna PublishingThe Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy1411-48012302-81812025-04-01261435410.24871/261202543-54916Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric AcidityRaymond Rubianto Tjandrawinata0Murdani Abdullah1Marcellus Simadibrata2Liana W Susanto3Kaka Renaldi4Atma Jaya Catholic University of Indonesia, Faculty of Biotechnology, Banten, Indonesia Dexa Laboratories of Biomolecular Sciences (DLBS), Cikarang, West Java, IndonesiaDivision of Gastroenterology, Department of Internal Medicine, dr. Cipto Mangunkusumo Hospital / Faculty of Medicine, University of Indonesia, Jakarta, IndonesiaDivision of Gastroenterology, Department of Internal Medicine, dr. Cipto Mangunkusumo Hospital / Faculty of Medicine, University of Indonesia, Jakarta, IndonesiaDexa Laboratories of Biomolecular Sciences (DLBS), Cikarang, West Java, IndonesiaDivision of Gastroenterology, Department of Internal Medicine, dr. Cipto Mangunkusumo Hospital / Faculty of Medicine, University of Indonesia, Jakarta, IndonesiaBackground: DLBS2411, A bioactive fraction derived from the bark of Cinnamomum burmanii has been developed to address acid-related gastrointestinal disorders. This study evaluated the pharmacodynamic effect of DLBS2411 on the 24-hour intragastric acidity in healthy adults.  Methods: In a 3-arm, parallel, double-blind, randomized, placebo-controlled clinical trial, healthy subjects received a single dose of DLBS2411 (250 mg or 500 mg) or placebo. Gastric pH was monitored, analyzed and profiled over 24 hours. Results: Of a total of 54 enrolled male subjects, 47 subjects (87.04%) were eligible for the analysis. The mean 24-hour intragastric pH for DLBS2411 250 mg and 500 mg was 2.29 ± 0.42 and 2.13 ± 0.50, respectively, both higher than placebo (1.93 ± 0.70). Differences were more pronounced during the first 12 hours (daytime). DLBS2411 250 mg and 500 mg reached a gastric pH 4 significantly faster (129.9 ± 128.2 and 92.9 ± 106.8 minutes) compared to placebo (196.9 ± 99.7 minutes). No serious adverse events occurred. All adverse events were mild and had been resolved by the end of study, confirming the safety and tolerability of DLBS2411 at the dose of 250 and 500 mg. Conclusion: DLBS2411 effectively suppressed the intragastric acidity and demonstrated a good safety profile in healthy adults. These findings warrant further studies of DLBS2411 in patients with gastric acid-related disorders. Keywords: Alternative medicine, DLBS2411 cinnamomum burmanii, healthy volunteers, intragastric-acidity, proton pump inhibitorshttps://ina-jghe.com/index.php/jghe/article/view/1059alternative medicine, dlbs2411 cinnamomum burmanii, healthy volunteers, intragastric-acidity, proton pump inhibitors
spellingShingle Raymond Rubianto Tjandrawinata
Murdani Abdullah
Marcellus Simadibrata
Liana W Susanto
Kaka Renaldi
Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric Acidity
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
alternative medicine, dlbs2411 cinnamomum burmanii, healthy volunteers, intragastric-acidity, proton pump inhibitors
title Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric Acidity
title_full Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric Acidity
title_fullStr Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric Acidity
title_full_unstemmed Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric Acidity
title_short Clinical Study of DLBS2411, a Mucoprotector and Proton Pump Inhibitor Bioactive Fraction Derived From Cinnamomum burmanii, on the Intragastric Acidity
title_sort clinical study of dlbs2411 a mucoprotector and proton pump inhibitor bioactive fraction derived from cinnamomum burmanii on the intragastric acidity
topic alternative medicine, dlbs2411 cinnamomum burmanii, healthy volunteers, intragastric-acidity, proton pump inhibitors
url https://ina-jghe.com/index.php/jghe/article/view/1059
work_keys_str_mv AT raymondrubiantotjandrawinata clinicalstudyofdlbs2411amucoprotectorandprotonpumpinhibitorbioactivefractionderivedfromcinnamomumburmaniiontheintragastricacidity
AT murdaniabdullah clinicalstudyofdlbs2411amucoprotectorandprotonpumpinhibitorbioactivefractionderivedfromcinnamomumburmaniiontheintragastricacidity
AT marcellussimadibrata clinicalstudyofdlbs2411amucoprotectorandprotonpumpinhibitorbioactivefractionderivedfromcinnamomumburmaniiontheintragastricacidity
AT lianawsusanto clinicalstudyofdlbs2411amucoprotectorandprotonpumpinhibitorbioactivefractionderivedfromcinnamomumburmaniiontheintragastricacidity
AT kakarenaldi clinicalstudyofdlbs2411amucoprotectorandprotonpumpinhibitorbioactivefractionderivedfromcinnamomumburmaniiontheintragastricacidity